Successful haematopoiesis requires long-term retention of haematopoietic stem cells (HSCs) in a quiescent state. The transcriptional regulation of stem cell quiescence, especially by factors with specific functions in HSCs, is only beginning to be understood. Here, we demonstrate that Nurr1, a nuclear receptor transcription factor, has such a regulatory role. Overexpression of Nurr1 drives early haematopoietic progenitors into quiescence. When stem cells overexpressing Nurr1 are transplanted into lethally irradiated mice, they localize to the bone marrow, but do not contribute to regeneration of the blood system. Furthermore, the loss of only one allele of Nurr1 is sufficient to induce HSCs to enter the cell cycle and proliferate. Molecular analysis revealed an association between Nurr1 overexpression and upregulation of the cell-cycle inhibitor p18 (also known as INK4C), suggesting a mechanism by which Nurr1 could regulate HSC quiescence. Our findings provide critical insight into the transcriptional control mechanisms that determine whether HSCs remain dormant or enter the cell cycle and begin to proliferate.
Successful haematopoiesis requires long-term retention of haematopoietic stem cells (HSCs) in a quiescent state. The transcriptional regulation of stem cell quiescence, especially by factors with specific functions in HSCs, is only beginning to be understood. Here, we demonstrate that Nurr1, a nuclear receptor transcription factor, has such a regulatory role. Overexpression of Nurr1 drives early haematopoietic progenitors into quiescence. When stem cells overexpressing Nurr1 are transplanted into lethally irradiated mice, they localize to the bone marrow, but do not contribute to regeneration of the blood system. Furthermore, the loss of only one allele of Nurr1 is sufficient to induce HSCs to enter the cell cycle and proliferate. Molecular analysis revealed an association between Nurr1 overexpression and upregulation of the cell-cycle inhibitor p18 (also known as INK4C), suggesting a mechanism by which Nurr1 could regulate HSC quiescence. Our findings provide critical insight into the transcriptional control mechanisms that determine whether HSCs remain dormant or enter the cell cycle and begin to proliferate.
Life-long haematopoiesis is sustained by the capacity of haematopoietic stem cells (HSCs) to self-renew as well as to replenish mature blood cells. Most HSCs reside in a quiescent or dormant state 1 , a property critical to maintain blood homeostasis. Mutations in a number of genes important for HSC quiescence lead to the loss of haematopoietic repopulating ability [2] [3] [4] . This strong correlation between HSC quiescence and regenerative capacity seems counterintuitive, but suggests that most HSC cell divisions (at least under stress) are symmetric, leading uniformly toward differentiation, rather than allowing HSC regeneration. Nevertheless, HSCs are clearly able to self-renew, as demonstrated by single-cell and secondary transplantation experiments 5 . Identifying the activities of genes that regulate self-renewal and differentiation is crucial to realizing the potential of HSCs in regenerative medicine.
The majority of genes known to have roles in HSC quiescence are those with essential functions in cell-cycle regulation (for example, p21, p27, D-type cyclins, RB and p53) 4, [6] [7] [8] [9] [10] or in transcriptional regulation of haematopoiesis (for example, Runx1, Egr1 and Gfi1) 2, 11, 12 .
To identify genes with a specific role in preservation of quiescence, we analysed genes that were differentially expressed between dormant and proliferating HSCs 13 , and uniquely expressed in HSCs 14 . Nurr1 (also known as Nr4a2) was identified as a prime candidate. This ligand-independent nuclear receptor-type transcription factor is paralogous to Nur77 and Nor1 (also known as Nr4a1 and Nr4a3, respectively) [15] [16] [17] [18] . Although combined loss of Nor1 and Nur77 results in an acute myeloid leukaemia (AML)-like phenotype in mice 19 , Nurr1 has not been implicated in haematopoiesis, although it is known to function in terminal differentiation of dopaminergic neurons 20, 21 , and regulation of apoptosis 22, 23 . Thus, the properties of Nurr1 were sufficiently relevant to warrant its further investigation for a role in HSC quiescence.
Quiescent HSCs proliferate in a synchronized manner after a single injection of the chemotherapeutic agent 5-flurouracil (5FU) 1, 13 . Microarray analysis of quiescent versus 5FU-stimulated HSCs identified approximately 800 genes that were activated in quiescent cells. One of these, Nurr1, was markedly downregulated in proliferating HSCs (Fig. 1a, b) , as well as in differentiated haematopoietic cells (Fig. 1c, d ). To examine whether Nurr1 expression in haematopoietic cells is functionally associated with quiescence, we forced its expression in 32D cells, an IL-3-dependent myeloid progenitor line, by transducing cells with a retrovirus carrying a vector containing Nurr1 upstream of IRES-GFP. This allowed us to follow the transduced cells through expression of green fluorescent protein (GFP; Fig. 1e ). An identical vector carrying only GFP was used as a control. Nurr1 overexpression led to a marked block in proliferation that inhibited expansion of the transduced 32D cells, whereas cells transduced with control vector readily proliferated (Fig. 1f) . To ensure that the difference in proliferation was not the result of apoptosis, we performed annexin-V staining. This demonstrated that there was no increase in cell death associated with Nurr1 overexpression (Fig. 1g) ; the proportion of apoptotic/ dead cells in the Nurr1-transduced group was significantly lower than in the control group (P = 0.004), consistent with a pro-survival role of Nurr1 (ref. 22) . Overexpression of Nurr1 in 32D cells also led to a decrease in cells positive for the proliferative marker Ki67 ( Supplementary Information,  Fig. 1a) , supporting an inhibitory effect of Nurr1 on proliferation. The
L E T T E R S
Nurr1-associated decrease in proliferation was not associated with increased differentiation of 32D cells (data not shown).
Although supporting the hypothesis that Nurr1 is a regulator of cell proliferation, these data do not demonstrate an effect on HSC cycling. Thus, we isolated bone marrow from 5FU-treated mice (to permit efficient transduction), magnetically enriched for progenitors using the Sca-1 stem cell marker, and transduced them with either of the vectors shown in Figure 1e (Fig. 2a) . After 2 days of culture to allow GFP expression, the GFP and Sca-1 double-positive cells were sorted for colony-forming assays, scored on day 14 of growth. The colony-forming ability of Nurr1-transduced cells was significantly reduced when compared with control cells (4% versus 20% of total wells of a 96-well plate, P = 0.0002; Fig. 2b ), suggesting that Nurr1 impedes proliferation of HSCs. The large decrease in colony number seen with Nurr1 overexpression could not be attributed to cytotoxicity, as the proportion of viable cells transduced with control and Nurr1-containing vectors were identical at the time of plating (data not shown). Annexin-V staining approximately 20 h after transduction indicated that the proportion of apoptotic cells was approximately 5% in both the control cells and in cells overexpressing Nurr1 (Fig. 2c) . Culture of more highly enriched progenitors for up to 96 h also resulted in no significant difference in cell viability ( Supplementary Information, Fig. 2a ), suggesting that Nurr1 overexpression is not toxic to HSCs. 
The in vitro data suggested that transplanted Nurr1-overexpressing cells would not be able to contribute to the replenishment of blood lineages in vivo. To test this, we transplanted haematopoietic progenitors transduced with control or Nurr1-containing vectors into lethally irradiated mice within approximately 4 h of transduction, thereby avoiding any effect that Nurr1 overexpression might have on homing (because the protein is not expressed immediately after transduction), and analysed the peripheral blood of recipients 4 weeks after transplantation for the presence of donor-derived transduced cells, using flow cytometry. Control-transduced cells were found to contribute to about 36% of the peripheral blood, whereas the contribution of Nurr1-transduced cells was only 0.43% (Fig. 2d) . Similar levels of nontransduced donor-derived cells were present between infusions of cells transduced with control vectors and vectors containing Nurr1, indicating successful transplantation. Flow-cytometric analysis performed 12 months post-transplantation revealed a persistent lack of contribution to peripheral blood from Nurr1-transduced donor cells, ruling out delayed engraftment ( Supplementary Information, Fig. 2b ). With so few Nurr1-overexpressing progeny, we cannot exclude a simultaneous impact of Nurr1 on proliferation and differentiation.
To explain the negligible contribution of Nurr1-overexpressing donor cells to peripheral blood reconstitution, we hypothesized that the transduced HSCs home to bone marrow, where they enter the cell cycle at very low levels, if at all. To verify their presence, the bone marrow and spleen were examined after transplantation. Non-transduced transplanted cells functioned as a background autofluorescence control. Four weeks post-transplantation, Nurr1-transduced GFP-positive cells were present in spleen and bone marrow (Fig. 2e ). Although these populations were small (< 1% of all cells in the tissues), they were significantly higher than the autofluorescent background levels of about 0.1%. The low proportion of Nurr1-overexpressing cells in the bone marrow seems similar to the proportion of transduced cells after initial transplantation. This suggests that control cells were able to proliferate and generate progeny, whereas the Nurr1-overexpressing cells remained dormant. As a single HSC can reconstitute a lethally irradiated mouse 24, 25 , we suggest that a sufficient number of transduced HSCs were present in the bone marrow to contribute to the reconstitution of peripheral blood; their inability to do so supports the hypothesis that Nurr1 is a regulator of cell proliferation.
To determine whether the proliferative block with Nurr1 overexpression is reversible, we used the Cre/loxP system. Nurr1 flanked by loxP sites was cloned into the retroviral vector shown in Figure 1e , and used to transduce cells expressing Cre recombinase under the control of a tamoxifeninducible promoter ( Supplementary Information, Fig. S3 ). Four weeks after transplantation of the transduced cells, tamoxifen was administered to half the group. As expected, mice transplanted with unfloxed Nurr1-overexpressing cells or control vector did not respond to tamoxifen treatment: Nurr1-transduced cells (measured by GFP) remained at very low levels, whereas control-vector-transduced cells were abundant. However, in mice transplanted with cells harbouring the floxed Nurr1 construct, there was an increase in GFP-expressing cells in peripheral blood 8 weeks after tamoxifen treatment, suggesting removal of the Nurr1-proliferative block with Nurr1 deletion (Fig. 2f) . The appearance of transduced cells 8 weeks after tamoxifen treatment supports the hypothesis that Nurr1 functions in HSCs rather than committed progenitors to restore depleted blood cell populations, and suggests that, as well as the dependency on niche occupancy, the timing of excision is also important.
The transplantation data, coupled with the in vitro data, indicate that Nurr1 overexpression restricts HSC proliferation. To directly determine the cell-cycle status of Nurr1-overexpressing cells, 48 h after transduction we sorted and stained GFP-expressing Sca-1-positive haematopoietic progenitors with pyronin Y and Hoechst 33342 dye, allowing us to distinguish between cells in G 0 versus G 1 . Flow-cytometric analysis revealed an approximate 50% increase of cells in G 0 with Nurr1 overexpression when compared with the control cells (Fig. 3a) , supporting an early block of HSC proliferation by Nurr1 activity.
To verify the physiologic relevance of Nurr1, we sought to determine whether the loss of Nurr1 expression would promote HSC proliferation. Homozygous Nurr1 knockout mice die shortly after birth due to defects in respiratory function 26 . ; SP-KSL) were plated onto methylcellulose, the colony-forming potential of progenitors from Nurr1 +/-mice was consistently higher than the control value (Fig. 3c) .
If greater numbers of HSCs with reduced levels of Nurr1 enter the cell cycle, they should be more sensitive to killing by anti-mitotic agents. To test this, we injected Nurr1 +/-and wild-type mice weekly with 5FU and then compared death rates between the two groups over 55 days. By 60 days after the first injection, only 2 of 5 wild-type mice had died, compared with 9 of 10 Nurr1 +/-mice (P = 0.022, Fig. 3d ), supporting our in vitro findings. When we examined the HSC population 7 days after 5FU injection, we observed a higher level of cell death in the HSCs from Nurr1 +/-mice ( Supplementary Information, Fig. 4a, b) . Thus, the exhaustion of the HSCs from Nurr1 +/-mice that leads to premature death after repeated 5FU injection is probably because of the higher level of HSC cycling (Fig.3b) , but a contribution from higher levels of apoptosis (potentially permitted by Nurr1 loss) cannot be excluded. Thus, both loss-and gain-of-function studies point to a physiologically important role for Nurr1 in HSC dormancy.
Next, we investigated how Nurr1 might exert its inhibitory effect on HSC proliferation. The expression levels of four cell cycle inhibitors (p18 INK4c, p19 INK4d, p21 C.p1/Waf1, and p27 Kip1) were measured in KSL progenitors from the livers of wild-type, Nurr1 +/-and Nurr1 -/-14.5-dayold embryos, the site of haematopoietic progenitors during this stage of development. The mRNA expression levels of p18, p19, p21 and p27 generally decreased with the loss of Nurr1 alleles (Fig. 4a) . To gain insight into the cell cycle phase affected by Nurr1, we sorted Nurr1-transduced HSCs for real-time PCR analysis. Interestingly, p18, but not p19, p21 or p27, was upregulated in Nurr1-overexpressing HSCs (Fig. 4b) , although there seemed to be a slight increase in p19 levels in a more heterogeneous progenitor population ( Supplementary Information, Fig. 5a ). p18 and p19 are inhibitors of the cyclin D-CDK4-CDK6 complex needed for cell-cycle progression through G 1 , whereas p21 and p27 inhibit laterappearing cyclin-CDK complexes. This indicates that Nurr1 activates cell-cycle inhibitors specific for progression through G 1 , rather than later cell-cycle phases. To confirm upregulation of p18 at the protein level on Nurr1 overexpression, 32D cells were transduced with a control vector or a vector encoding Flag-tagged Nurr1. After 4 days of culture (optimal based on earlier experiments; Fig. 1f ), protein levels of p18 and p19 were determined by western blot analysis. The results showed a significant increase (P = 0.011) in p18 but not p19 levels with Nurr1 overexpression (Fig. 4c) , suggesting that the inhibitory effects of Nurr1 on HSC self-renewal and differentiation may be mediated by p18. This could be direct or indirect activation of p18, as we observed no Nurr1-binding sequence in the p18 promoter.
To determine whether the hyper-proliferation phenotype of Nurr1 +/-mice could be relieved by forcibly expressing p18, we expressed p18 from a retrovirus in haematopoietic progenitors from Nurr1 +/-mice. Cell-cycle analysis demonstrated reduced progenitor proliferation when compared with cells transduced with the control vector (Fig. 4d) . Furthermore, when p18 expression was forced in cells from Nurr1 +/-mice, their proliferative advantage relative to cells from wild-type mice was lost (Fig. 4e) , thereby relieving the Nurr1 +/-over-proliferation phenotype. Enforced expression of Nurr1 in p18-null cells was not able to cause the proliferation block as it does in wild-type cells ( Supplementary Information, Fig. 5b, c) , consistent with a role for p18 downstream of Nurr1.
Here, we show that Nurr1 tightly regulates HSC quiescence. Loss of only a single allele of Nurr1 in HSCs results in their enhanced cycling and sensitivity to the anti-mitotic agent 5FU. By contrast, overexpression of Nurr1 inhibits proliferation of the haematopoietic progenitor cell line 32D, as well as that of bone-marrow progenitors plated in vitro. Remarkably, Nurr1 overexpression in transplanted HSCs inhibits their proliferation, but this block is released when Nurr1 is deleted with the Cre recombinase. Finally, consistent with its role in retaining HSCs in G 0 , Nurr1 appears to function through upregulation of the early G 1 -phase cell-cycle inhibitor p18.
In general, genes known to have a role in HSC dormancy have a broad function in many different tissues. Only a few transcription factors besides Nurr1 with purported roles in quiescence have expression patterns restricted to haematopoietic progenitors. One of these, the PR-domain-containing transcription factor Evi1, is expressed in HSCs at level approximately 1000-fold higher than in differentiated haematopoietic cells 14 and is involved in leukaemia generation through chromosomal translocation 27 . Necdin is another transcription factor that has much higher expression in HSCs than differentiated haematopoietic cells 14, 28 , but it appears to have a modest functional role in HSCs 4, 28 . Importantly, overexpression of Necdin fails to impose quiescence in HSC as does Nurr1 (J. Berg and M.A.G., unpublished observations).
Although Nurr1 expression seems to be restricted to haematopoietic progenitors, the paralogues Nur77 and Nor1 are expressed in progenitors and myeloid cells. Mice deficient in Nur77 and Nor1 died 2-4 weeks after birth with an AML phenotype 19 . Furthermore, leukaemic blasts from AML patients demonstrated downregulation of NUR77 and NOR1, consistent with a role in the proliferation of haematopoietic progenitors 19 . As both Nur77 and Nor1 are expressed in mouse HSCs and bind to the same DNA sequence recognized by Nurr1 (refs 29-31) , we suggest that all three may cooperate to maintain HSC dormancy.
To identify mechanisms by which Nurr1 may regulate quiescence, we measured expression of four cell-cycle inhibitors associated with modulation of HSC proliferation 6, 7, [32] [33] [34] . Only p18 was unequivocally upregulated on Nurr1 overexpression. As p18 is hypothesised to preserve HSC function by limiting cell-cycle entry 34 , its regulation by Nurr1 provides a plausible mechanism for the effects of Nurr1 overexpression or deletion seen in this study. Whether Nurr1 targets the p18 gene directly or indirectly remains to be determined.
Because of the importance of Nurr1 in brain development, its role in this tissue has been extensively studied. Recently, it was shown to interact with co-repressor for element-1-silencing transcription factor (CoREST) to protect neurons from inflammation-induced apoptosis 35 . Nurr1 may have a similar role in HSCs during inflammatory stress 36 . Nurr1 has also been shown to interact with Pitx3, to prevent apoptosis in the brain 37, 38 .
Although not detected in mature haematopoietic cells, Pitx1 is highly expressed in HSCs 14 , suggesting that common mechanisms may regulate parallel processes in HSCs and developing neurons.
Our studies provide critical insight into the transcriptional machinery that protects HSCs from excessive proliferation that could lead to stem cell exhaustion. Taken in the context of other transcription factors that regulate HSC proliferation such as Gfi1, Mef1/E1f4, GATA2, and members of the FoxO family 12, 39, 40 , Nurr1 seems to be part of an intrinsic core regulatory circuit that maintains HSC quiescence, much in the way that Nanog, Oct4 or Sox2 control the pluripotency of embryonic stem cells 41 . Understanding how each of these components functions, and the degree of cross-talk among them, will be crucial to manipulating HSC toward desired therapeutic end-points. ) and observed daily for changes in physical health. The times of death were scored and converted to survival plots, with the Gehan-BreslowWilcoxon test used to assess statistical significance.
METHODS
Real-time PCR Analysis. After RNA isolation in lysis buffer (GE Healthcare), reverse transcription was performed with random hexamer primers and the Superscript II kit (Invitrogen). The cDNA was then used in PCR amplifications with either Taqman mastermix, an 18 s ribosomoal RNA probe (VIC-MGB), and a genespecific probe (FAM-MGB, Applied Biosystems) or Sybrgreen mastermix and primers targeting the gene of interest as well as GAPDH (for normalization). Reactions were run with an AbiPrism 7900HT (Applied Biosystems) for 40 cycles. Statistics. Descriptive statistics (means and standard deviations) were used to summarize normally distributed data and the two tailed t-test was used to compare results. Differences with a P value of < 0.05 were considered statistically significant. The Gehan-Breslow-Wilcoxon test used to assess statistical significance in survival assays. 
